Category: Article - Page 2 - Nanostics Precision Health

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test

perrin2024-04-23T12:23:50+00:00

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test
ClarityDX Prostate is a blood test that combines biological and clinical information using machine learning to generate a risk score for aggressive prostate cancer

EDMONTON, ALBERTA – April 23 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics’ ClarityDX Prostate® test in North America.

Funds raised through the UAIF will go towards expanding access to ClarityDX Prostate across North America and supporting the expansion of its product pipeline, including the development of ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test.

ClarityDX Prostate is currently available in Canada as a laboratory-developed test. For more information or to order the test please visit nanosticsdx.com.

Click below to read the full press release.

Press Release

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Testperrin2024-04-23T12:23:50+00:00

Prostate Cancer Screening in 2024

perrin2024-04-22T23:57:03+00:00

Dr. Chris Wallis talks about the benefits and harms of prostate cancer screening in 2024 using PSA and the addition of adjunctive tests like ClarityDX Prostate.

Video

Prostate Cancer Screening in 2024perrin2024-04-22T23:57:03+00:00

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases

perrin2024-04-11T17:16:42+00:00

Nanostics and Alberta Health Services (AHS) agreement enables collaboration with AHS data scientists to develop new tools to improve the diagnosis of urological diseases.
This collaboration will leverage Alberta’s comprehensive digital healthcare assets to improve patient care while satisfying all AHS privacy concerns.

EDMONTON, ALBERTA – April 9th – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is excited to announce a partnership with Cancer Care Alberta, Alberta Health Services (AHS) to leverage advanced data analytics from Connect Care and the Cancer Care Alberta Data Environment for Cancer Inquiries and Decisions (DECIDe). This agreement will streamline access to Connect Care’s powerful and consolidated “one record, one patient, one health clinical information system” to help drive diagnostic and prognostic innovations in urological care in Alberta.

Click below to read the full press release.

Press Release

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseasesperrin2024-04-11T17:16:42+00:00

ClarityDX Prostate Physician Brochure

perrin2024-06-28T20:59:39+00:00

Click Here for the ClarityDX Prostate Healthcare Provider Brochure

ClarityDX Prostate Physician Brochureperrin2024-06-28T20:59:39+00:00

ClarityDX Prostate Patient Brochure

perrin2024-06-28T20:49:39+00:00

Click Here for the ClarityDX Prostate Patient Brochure

ClarityDX Prostate Patient Brochureperrin2024-06-28T20:49:39+00:00

ClarityDX Prostate Breakthrough Prostate Cancer Test

perrin2024-04-22T23:51:02+00:00

ClarityDX Prostate is a breakthrough test that significantly advances prostate cancer screening. It provides critical support to men and their primary care providers in making more informed decisions, with 3X the accuracy, about whether a biopsy is required following a high prostate-specific antigen (PSA) test result.

Video

ClarityDX Prostate Breakthrough Prostate Cancer Testperrin2024-04-22T23:51:02+00:00

ClarityDX Prostate is Revolutionizing Prostate Cancer Detection

perrin2024-01-10T22:05:14+00:00

Disruption Magazine Special Issue 21

A Better Way: How Nanostics is Revolutionizing Prostate Cancer Detection

“Any jurisdiction in the world can adopt our test. It’s got huge potential.” Nanostics Chief Commercialization Officer Colin Coros

In the realm of medical innovation, success stories often find their roots in personal journeys. Such is the case with Nanostics, a pioneering company in the field of prostate cancer diagnostics. The tale begins with Frank Sojonky, an Alberta businessman, who, upon facing a prostate cancer diagnosis, embarked on a mission to revolutionize the landscape of prostate cancer research and testing.

Sojonky’s dissatisfaction with the lack of focus on prostate cancer research in Alberta led to the creation of the Bird Dogs for Prostate Cancer Research organization in partnership with the Alberta Cancer Foundation. The organization ultimately raised more than $20 million to establish a translational research program, known as the Alberta Prostate Cancer Research Initiative, headed by CEO Dr. John Lewis. It evolved into the world’s largest repository for prostate cancer patient samples, and with a focus on translation, those samples became instrumental in developing new therapeutics and diagnostic tests.

Click below to read the full article.

Article

ClarityDX Prostate is Revolutionizing Prostate Cancer Detectionperrin2024-01-10T22:05:14+00:00

Nanostics Launches ClarityDX Prostate Test in Alberta to Significantly Improve Prostate Cancer Screening

perrin2024-01-10T22:12:10+00:00

EDMONTON, ALBERTA – September 28 – Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta. This innovative blood test marks a significant advancement in prostate cancer screening. It provides critical support to men, aged 40 to 75, and their physicians in making more informed decisions, with 3X the accuracy, about whether a biopsy is required following a high prostate-specific antigen (PSA) test result.

According to Dr. John D. Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta, “This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk.” Notably, research shows that adding ClarityDX Prostate to the patient care pathway could reduce unnecessary prostate biopsies by up to 35% and yield significant cost savings.

Click below to read the full press release.

Press Release

Nanostics Launches ClarityDX Prostate Test in Alberta to Significantly Improve Prostate Cancer Screeningperrin2024-01-10T22:12:10+00:00

Nanostics Clinical Lab Granted Provisional CPSA Accreditation

perrin2023-09-18T16:18:46+00:00

CPSA https://cpsa.ca/facilities-clinics/accreditation/

With this provisional accreditation from the College of Physicians and Surgeons of Alberta (CPSA), Nanostics clinical laboratory in Edmonton can now begin providing its ClarityDX Prostate test to patients.

EDMONTON, AB, September 07, 2023 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that the College of Physicians and Surgeons of Alberta (CPSA) granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada. This important achievement means that Nanostics’ Clinical Laboratory, led by Medical Laboratory Director, Dr. Todd McMullen, can start providing the ClarityDX Prostate® test to patients.

“We are thrilled to receive CPSA accreditation because we can offer our test from our new clinical lab in Edmonton,” said John Lewis, CEO of Nanostics. “This is another major step towards ensuring men facing prostate cancer have access to the best tools that can aid them in managing this devastating disease.”

The ClarityDX Prostate test, validated in men from five clinical sites across Canada, the United States, and Czechia, is a simple and rapid test that accurately predicts the risk of having clinically significant prostate cancer. ClarityDX Prostate is intended to be used by men with elevated levels of PSA and is designed to help physicians and patients make a more informed decision on whether or not to proceed with a biopsy.

CPSA ensures the safety and quality of medical and diagnostic testing services in Alberta through an independent accreditation program. Any Alberta laboratory that performs and reports diagnostic tests to guide patient care needs to be CPSA accredited. It’s a rigorous assessment process based on Quality Management Systems, which are recognized by international healthcare external evaluation organizations.

“Nanostics’ has always been dedicated to exceptional operational standards with a strong commitment to quality performance” said Todd McMullen, Medical Laboratory Director of Nanostics. “CPSA accreditation highlights our commitment to quality and will provide patients with the confidence they need to trust our services.”

Press Release

Nanostics Clinical Lab Granted Provisional CPSA Accreditationperrin2023-09-18T16:18:46+00:00

EV-Fingerprint test predicts aggressive prostate cancer

perrin2023-09-02T22:04:14+00:00

Published 17 June 2023

Clinical analysis of EV- Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy

Adrian Fairey, Robert J. Paproski, Desmond Pink, Deborah L. Sosnowski, Catalina Vasquez, Bryan Donnelly, Eric Hyndman, Armen Aprikian, Adam Kinnaird, Perrin H. Beatty, John D. Lewis

Abstract

There is an unmet clinical need for minimally invasive diagnostic tests to improve the detection of grade group (GG) ≥3 prostate cancer relative to prostate antigen-specific risk calculators. We determined the accuracy of the blood-based extracellular vesicle (EV) biomarker assay (EV Fingerprint test) at the point of a prostate biopsy decision to predict GG ≥3 from GG ≤2 and avoid unnecessary biopsies.

This study analyzed 415 men referred to urology clinics and scheduled for a prostate biopsy, were recruited to the APCaRI 01 prospective cohort study. The EV machine learning analysis platform was used to generate predictive EV models from microflow data. Logistic regression was then used to analyze the combined EV models and patient clinical data and generate the patients’ risk score for GG ≥3 prostate cancer.

The EV-Fingerprint test was evaluated using the area under the curve (AUC) in discrimination of GG ≥3 from GG ≤2 and benign disease on initial biopsy. EV-Fingerprint identified GG ≥3 cancer patients with high accuracy (0.81 AUC) at 95% sensitivity and 97% negative predictive value. Using a 7.85% probability cutoff, 95% of men with GG ≥3 would have been recommended a biopsy while avoiding 144 unnecessary biopsies (35%) and missing four GG ≥3 cancers (5%). Conversely, a 5% cutoff would have avoided 31 unnecessary biopsies (7%), missing no GG ≥3 cancers (0%).

EV-Fingerprint accurately predicted GG ≥3 prostate cancer and would have significantly reduced unnecessary prostate biopsies.

Full Article

EV-Fingerprint test predicts aggressive prostate cancerperrin2023-09-02T22:04:14+00:00

Follow Us

Contact Us